Lifecare : LIFE Longevity trials in dogs starts today

LIFE Longevity trials in dogs starts today

18 Jun 2024 08:00 CEST

Subscribe

Issuer

Lifecare ASA

Bergen, Norway, 18 June 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that the company will starts the longevity trials in
dogs today.

Reference is made to stock exchange notification June 10th and June 13th,
2024. The company have improved the read-out distance from sensor to the
read-out device and the internal in-vitro quality test has been successfully
conducted.

The longevity study on dogs will be performed at the Norwegian University of
Life Sciences (NMBU), located in Ås, close to Oslo. Managing Director, Jo
Amundstad of the subsidiary Lifecare Veterinary, will be responsible for
carrying out the study in collaboration with NMBU.

-- We have carried out the necessary preparations and procedures of the
longevity study. The team consists of some of the leading experts in internal
medicine at NMBU and their important contribution towards the study we are
starting now is highly valued. Recruitment of patients has worked out as
planned and the first dog is ready for implementation of the wireless sensor
today, says Jo Amunstad.

Last week Lifecare Laboratory in Mainz conducted the in-vitro quality test of
the wireless communication between the sensor and a read-out device. In their
report they have concluded that the read-out signals from the sensor in the
in-vitro testing environment meets necessary requirements from a product
development perspective. Hence the company are ready to start the longevity
study in dogs in today.

- The results and learnings from the longevity study and the ongoing progress
towards automated production are important steps towards product readiness in
the veterinary market, says CEO Joacim Holter at Lifecare.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, [e-mail], [phone]

Renete Kaarvik, CFO, [e-mail], [phone]

More information:
Access the news on Oslo Bors NewsWeb site

621746_LIFE Longevity trials in dogs starts today.pdf

Source

Lifecare ASA

Provider

Oslo Børs Newspoint

Company Name

LIFECARE ASA

ISIN

NO0010591191

Symbol

LIFE

Market

Euronext Growth